Effect and mechanism of pirfenidone combined with 2-methoxy-estradiol perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis
Advances in Medical Sciences · 2023
DOI: 10.1016/j.advms.2022.12.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Medical Sciences, 2023. Verfasst von Hui Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China. Hauptthemen laut MEDLINE: Hepatic Artery, Portal Vein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Fujian Medical University.
Abstract (Originalsprache)
PURPOSE: The aim of this study was to explore the effect and mechanism of pirfenidone (PFD) combined with 2-methoxyestradiol (2-ME2) perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis. MATERIALS AND METHODS: Sprague-Dawley rats were divided into 5 groups (n = 3/group): control group, hepatic artery ligation (HAL) group, HAL + PFD (portal vein perfusion of PFD) group, HAL+2-ME2 (portal vein perfusion of 2-ME2) group and HAL + PFD+2-ME2 group depending on whether they received HAL and/or portal vein perfusion (PFD and/or 2-ME2). Livers were harvested for pathology, western blotting (WB), and quantitative real-time PCR (qRT-PCR). RESULTS: Sirius red staining showed that portal vein perfusion of drugs resulted in degradation of liver fibrosis. Immunohistochemistry showed decreased hypoxia-inducible factor-1 α (HIF-1α) and α-smooth muscle actin (α-SMA) after portal intravenous drugs infusion compared with HAL group (P < 0.05). WB analysis showed increased Smad7 in HAL + PFD group compared with HAL group (P < 0.05). qRT-PCR analysis showed decreased matrix metallo-proteinase 2 (MMP2), transforming growth factor β1 (TGF-β1), monocyte chemoattractant protein-1 (MCP-1), and Collagen I mRNA in HAL + PFD group except for tissue inhibitor of metalloproteinase-1 (TIMP-1) compared with HAL group (P < 0.05). Compared with HAL + PFD group, the addition of 2-ME2 did not lead to better results in qRT-PCR analysis. CONCLUSIONS: The portal vein perfusion of PFD significantly reduced the hepatic artery hypoxia-induced fibrosis degree in treated rats by down-regulating the expression of HIF-1α, α-SMA, MMP2, TGF-β1, MCP-1, and Collagen I, as well as up-regulating the TIMP-1 expression and Smad7 protein level. Combined 2-ME2 infusion was not better than PFD alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
- Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China; Department of Interventional Therapy, Xiamen Humanity Hospital, Xiamen, Fujian, People's Repu…
- Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China. Electronic address: yangwz2022@163.com.
Förderung
- Fujian Medical University
Zitieren
APA
Zheng, H., Huang, N., Lin, J. Q., Yan, L. Y., Jiang, Q. G., & Yang, W. Z. (2023). Effect and mechanism of pirfenidone combined with 2-methoxy-estradiol perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis. Advances in Medical Sciences. https://doi.org/10.1016/j.advms.2022.12.001
Vancouver
Zheng H, Huang N, Lin JQ, Yan LY, Jiang QG, Yang WZ. Effect and mechanism of pirfenidone combined with 2-methoxy-estradiol perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis. Advances in Medical Sciences. 2023. doi:10.1016/j.advms.2022.12.001
BibTeX
@article{Zheng2023,
author = {Zheng, Hui and Huang, Ning and Lin, Jun-Qing and Yan, Le-Ye and Jiang, Qing-Gui and Yang, Wei-Zhu},
title = {Effect and mechanism of pirfenidone combined with 2-methoxy-estradiol perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis},
journal = {Advances in Medical Sciences},
year = {2023},
doi = {10.1016/j.advms.2022.12.001}
}
EUVIMED